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Abstract
Identiﬁcation of ROS1 rearrangements in patients with lung cancer allows them to beneﬁt from targeted
therapy. We compared immunohistochemistry (IHC) with more cumbersome methods such as ﬂuorescence in
situ hybridization and reverse transcriptase polymerase chain reaction for identiﬁcation of ROS1 rearrange-
ments in patients with lung adenocarcinoma (n [ 33). Our results showed that IHC is a sensitive (100%) and
speciﬁc (100%) method to identify ROS1 rearrangements in patients with lung cancer.
Background: ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase re-
ceptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung
adenocarcinoma with ROS1 gene fusions. Although ﬂuorescence in situ hybridization (FISH) is the standard diagnostic
procedure for detecting ROS1 rearrangements, we studied immunohistochemistry (IHC). Materials and Methods:
ROS1 IHC was performed on a selected cohort of 33 lung adenocarcinoma whole tissue specimens with alterations in
the EGFR (n ¼ 5), KRAS (n ¼ 5), ERBB2 (HER2) (n ¼ 3), ROS1 (n ¼ 6), ALK (n ¼ 5), and RET (n ¼ 3) genes and pan-
negative (n ¼ 6) detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and FISH. Results: In the
cohort of 33 specimens, both ROS1 gene fusion using RT-PCR and high ROS1 protein expression using IHC were
detected in 6 specimens. Of these 6 specimens, 5 were also positive by FISH for ROS1 gene rearrangements. All 27
lung cancer specimens that were negative for ROS1 rearrangements by genetic testing had no to low ROS1 protein
expression. Conclusion: We have optimized ROS1 IHC and scoring to provide high sensitivity and speciﬁcity for
detecting ROS1 gene rearrangements in whole tissue. ROS1 IHC could be a practical and cost-effective method to
screen for ROS1 gene rearrangements.
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Lung cancer is at the forefront of precision therapy for solid tu-
mors with a rapidly advancing understanding of the genetic drivers.
Many of these genetic changes are mutually exclusive, with just 1
genetic change as the cancer driver. Practical methods and standards*This is an open access article under the CC BY-NC-SA license (http://
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1for the identiﬁcation of mutations in lung cancer specimens have
become increasingly important to ensure that patients with genetic
alterations are identiﬁed and receive the most effective therapy.1-3
ROS1 is a receptor tyrosine kinase that is overexpressed when the
ROS1 gene is constitutively activated by gene rearrangement. ROS1
gene rearrangements were initially identiﬁed in glioblastoma1 and
cholangiocarcinoma2 and, in 2007, for lung cancer.3 ROS1 rear-
rangements have also been identiﬁed in cases of gastric cancer,4
colorectal cancer,5 ovarian cancer,6 and angiosarcoma.7 In these
cancers, fusions of the ROS1 gene with multiple gene partners have
been observed.8 The treatment of patients with ROS1 gene rear-
rangements with crizotinib and other directed therapies has shown
high clinical efﬁcacy.9-12
Although ROS1 rearrangements have been identiﬁed in only 1%
to 2% of nonesmall-cell lung carcinoma (NSCLC) cases,10,13 they
are present in a greater percentage of tumors that lack other genetic
changes associated with lung cancer.14 Limited data have also sug-
gested that, similar to EGFR mutations and ALK rearrangements,
ROS1 rearrangements are more common in certain subsets of the525-7304/$ - see frontmatter ª 2015 The Authors. Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cllc.2014.10.003
population, such as young Asian patients with a negative smoking
history.10,15 A study of never smoker patients with lung adenocar-
cinoma treated at Severance Hospital in Seoul, Korea, detected
ROS1 rearrangements by ﬂuorescence in situ hybridization (FISH)
in 5.7% (6 of 105) of patients who were “triple negative” for EGFR,
KRAS, and ALK alterations.14 Likewise, a study of a selected pop-
ulation of white patients with “triple-negative” NSCLC found a
7.4% (9 of 121) positivity rate for ROS1 rearrangements using
FISH and immunohistochemistry (IHC).16
The detection of ROS1 rearrangements in lung cancer specimens
has been hampered by issues similar to those described for the
detection of ALK rearrangements.17 Both ROS1 and ALK gene
rearrangements are present in a low percentage of cases and can
occur with multiple fusion partners. FISH can detect multiple
rearrangements by a split signal but is a cumbersome and expensive
method. Reverse transcriptase polymerase chain reaction (RT-PCR)
is also possible but requires multiple primer sets, and rare rear-
rangements can be missed. ROS1 IHC requires less labor, is less
expensive, and is more widely available than FISH and RT-PCR.
ROS1 proteins are not highly expressed in normal lung tissue,
and gene rearrangements have been associated with high ROS1
protein expression. Thus, IHC is an ideal method to screen for lung
cancer cases with ROS1 gene rearrangements.18-21 In the present
study, we have built on the work of others to examine the corre-
lation of ROS1 protein expression with the presence of ROS1 gene
rearrangements. We describe our criteria for ROS1 IHC positivity
using the histology score (H-score) and demonstrate how IHC can
be an effective method to screen for ROS1 gene rearrangements. In
addition, we have described the clinicopathologic features of lung
cancers associated with ROS1 gene rearrangements.
Materials and Methods
Case Selection
Our “selected cohort” was split into 2 rounds of testing of whole
tissue lung adenocarcinoma specimens. The ﬁrst round included 20
specimens enriched for ROS1 gene rearrangements (n ¼ 6), EGFR
mutations (n¼ 5), and KRASmutations (n¼ 3) previously detected
by RT-PCR and/or FISH. Six specimens were pan-negative for
ROS1, EGFR, KRAS, BRAF, ERBB2 (HER2), ALK, and RET gene
abnormalities. The H-score results of this ﬁrst round of IHC were
correlated with the RT-PCR and FISH results to deﬁne an H-score
cutoff for “positive” versus “negative.” A second round of testing
with 13 additional adenocarcinoma specimens was performed to
validate the H-score cutoff deﬁned in the ﬁrst round of testing. The
specimens in this second round were positive for ALK rearrange-
ments (n¼ 5), KRASmutations (n¼ 2), ERBB2 (HER2)mutations
(n¼ 3), and RET gene rearrangements (n¼ 3) and all were negative
for ROS1 rearrangements using RT-PCR. The present study was ap-
proved by the institutional review board of the Aichi Cancer Center.
Immunohistochemistry
Optimization for ROS1 IHC was performed using clone D4D6
(Cell Signaling Technology, Danvers, MA). The HCC78 cell line
with the SLC34A2-ROS1 gene fusion was selected as a positive
control. The HCC1703 cell line was used for a negative control.
IHC was performed on unstained parafﬁn-embedded tissue sec-
tions. The whole tissue slides from the selected cohort were stainedwith an automated procedure. The slides were dried in a 60C oven
for 1 hour, labeled with a bar-coded, standardized, antibody-speciﬁc
protocol, and loaded into a Benchmark XT automated stainer
(Ventana Medical Systems, Tucson, AZ). The slides were treated
with standard cell conditioning 1 reagent for 60 minutes. The
primary antibody (clone D4D6, Cell Signaling Technology,
Danvers, MA) was manually applied at 1:100 and 1:250 dilutions,
and the slides were incubated at 37C for 1 hour. Ampliﬁcation and
detection were performed using the UltraView Ampliﬁcation and
DAB detection kits. The slides were counterstained with hema-
toxylin for 4 minutes and post-counterstained with bluing agent for
4 minutes. The slides were then washed with mild detergent and
dehydrated in a series of 70% to 100% alcohol baths, cleared in a
xylene bath, and cover slipped.
The ROS1-stained slides were evaluated with the H-score by a
pathologist (T.B.), who was unaware of the RT-PCR and FISH
results in all the studies. The H-score is a semiquantitative score
system that calculates a score from 0 to 300 according to both the
intensity of tumor cytoplasmic staining and the percentage of cells
stained. For the present study, intensity was considered 0 for absent
expression, 1þ for weak staining, 2þ for moderate staining, and
3þ for strong staining. The H-score was calculated as follows:
H-score ¼ (0  percentage of cells with absent cytoplasmic
staining) þ (1  percentage of 1þ cells) þ (2  percentage of
2þ cells) þ (3  percentage of 3þ cells).
The specimens were scored only if  20 tumor cells were present.
Tissue areas in which it was difﬁcult to distinguish type II pneu-
mocyte hyperplasia from adenocarcinoma in situ were excluded
from scoring, because previous studies have warned that hyper-
plastic type II pneumocytes can exhibit ROS1 protein expression
and can result in false positivity.19
RT-PCR and FISH
RT-PCR with sequencing was performed for EGFR, KRAS,
ERBB2 (HER2), ROS1, ALK, and RET alterations, as previously
described.8,10,22-25 RT-PCR for ROS1 rearrangements was per-
formed to detect the following known ROS1 gene fusion partners:
CD74, SLC34A2, LRIG3, SDC4, SLCA2, TMP, and EZR. In brief,
total RNA was reverse transcribed to cDNA and then subjected to
ampliﬁcation with fusion-speciﬁc primers. Gel electrophoresis was
performed with follow-up Sanger sequencing on PCR products
with visible bands. FISH assays were performed for ALK, RET, and
ROS1 using commercially available probe sets (Vysis), as previously
described.25
Results
Test Cohort
The ﬁrst round of ROS1 IHC testing of 20 whole tissue speci-
mens was performed using 1:100 and 1:250 dilutions of the D4D6
antibody. Six specimens with ROS1 rearrangements previously
detected by RT-PCR exhibited strong staining (Figures 1 and 2).
The calculated H-scores were > 100 for all 6 specimens (mean,
197; range, 130-270). FISH was positive in 5 of the 6 specimens
with ROS1 rearrangements detected by RT-PCR and IHC.
The histopathologic features of the 6 ROS1 IHC-positive spec-
imens are summarized in Table 1. Three had CD74 gene fusions, and
three had different fusion partners: SCL34, EZR, and SDC4. AllClinical Lung Cancer March 2015 - 107
Figure 1 Microscopic Images of Specimens With Positive ROS1 Immunohistochemistry (A-F Correlate With Specimens 1-6 in Table 1,
Respectively; All Original Magniﬁcation 3400)
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108 -6 tumors were adenocarcinoma; 4 had a predominantly solid pattern,
1 acinar, and 1 lepidic. Of the 6 tumors, 3 were mucinous, of which,
2 also had signet ring cells. All 6 tumors had at least some areas with a
cribriform pattern. All had ﬁnely granular cytoplasmic staining for
ROS1; however, the specimen with the EZR fusion partner also
showed strong membrane staining (Figure 1E). Of the 3 specimens
with CD74 as a fusion partner, 2 had ROS1-positive globules within
the cytoplasm of a proportion of the tumor cells (Figure 1C and 1D).
Of the specimens that were negative for the ROS1 rearrange-
ments by RT-PCR, all had IHC H-scores of  100 at both di-
lutions (mean, 17; range, 0-100). Thus, ROS1 H-score cutoffs from
100 to 130 were associated with perfect correlation of the ROS1
IHC and RT-PCR results (100% sensitivity and 100% speciﬁcity).
Four specimens that were negative for ROS1 rearrangements byClinical Lung Cancer March 2015FISH exhibited low ROS1 protein expression by IHC, with
H-scores ranging from 5 to 100 (Figure 3). Considering the clean
background at both dilutions and a need for high sensitivity for
ROS1 rearrangement detection, a dilution of 1:100 was selected for
our ROS1 IHC protocol.
A second round with testing of 13 additional specimens known
to be negative for ROS1 rearrangement by RT-PCR was performed
to test the speciﬁcity of an H-score cutoff of 100. The speciﬁcity
for this second round of testing was again 100%, with all
H-scores < 100 (mean, 3.1; range, 0-30; Figure 2).
Discussion
Our data have described ROS1 IHC as a method for detection
and screening of lung cancer whole tissue specimens for ROS1 gene
Figure 2 Histology Score (H-score) for Specimens in Selected Cohort. The First 6 Specimens Were ROS1-Rearrangement Positive. The
Remainder Were ROS1-Rearrangement Negative
Abbreviations: NSCLC ¼ nonesmall-cell lung cancer; RT-PCR ¼ reverse transcriptase polymerase chain reaction.
Theresa A. Boyle et alrearrangements. We used the same antibody (D4D6) for ROS1
IHC staining as others have used19,26 and conﬁrmed ROS1 IHC as
a highly sensitive method for the detection of ROS1 translocation in
lung cancer. An algorithm with the detection of ROS1 and ALK
rearrangements (6%-7%), EGFR mutations (10%-20%), and KRAS
mutations (approximately 25%) in lung adenocarcinoma specimens
would identify driver mutations in approximately one half of all
patients with lung adenocarcinoma.
A comparison of the ROS1 IHC data with the RT-PCR results
showed a perfect correlation (100% sensitivity and 100% speci-
ﬁcity) in our small selected cohort when a positive result was deﬁned
as an H-score > 100. After we had established an H-score cutoffTable 1 Histopathologic Features of ROS1 Rearrangement-Positive
Specimen
Fusion
Partner H-Score Staining Pattern
1611 SCL34 170 Granular cytoplasmic
1958 CD74 130 Granular cytoplasmic
2006 CD74 200 Cytoplasmic; focal globular
2087 CD74 170 Strongly globular (30%)
2604 EZR 200 Membranous; cytoplasmic
2647 SDC4 270 Granular cytoplasmicinternally, Cha et al27 published their ﬁndings on ROS1 IHC using
the same antibody and methods and also determined an H-score of
> 100 as their cutoff for positivity, with a sensitivity of 100% for 8
ROS1-rearranged cases. Thus, we have conﬁrmed their ﬁndings and
propose the IHC method and an H-score cutoff of 100 for stan-
dardized testing to screen patients for ROS1 rearrangements.
Of the 6 specimens with a ROS1 rearrangement detected by
RT-PCR and IHC, 1 was negative by FISH. This specimen with
the discrepant negative FISH result had an EZR fusion partner
detected using RT-PCR. The EZR gene is on the same chromosome
as the ROS1 gene, such that detection by FISH technology might be
more complicated than for fusion genes on different chromosomes.Specimens (n [ 6)
Mucinous Signet Ring Cribriform
Predominant
Pattern
No No Yes Solid
Yes Yes (75%) Yes (focal) Solid/signet ring
Yes Yes (5%) Yes Acinar/solid
No No Yes Lepidic
Yes No Yes Solid/lepidic
No No Yes Solid
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Figure 3 (A-D) Borderline Cases With Some Tumor Cells Very Weakly Positive by Immunohistochemistry (Histology Score < 100). All
Were Negative for ROS1 Gene Rearrangement (Original Magniﬁcation 3400 for All)
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fusions and normal ﬁndings using FISH, because the signals for
these 2 genes are located on the same chromosome, regardless of
fusion. Therefore, IHC and RT-PCR might be superior to FISH in
detecting ROS1 rearrangements caused by ROS1-EZR fusions.
Our histopathologic ﬁndings, summarized in Table 1, add to
the descriptions of others regarding the appearance of specimens
with ROS1 rearrangements. We had a high proportion of speci-
mens with cribriform (100%), mucinous (50%), and signet
ring (33%) features.19,26 We also can support the observations of
Yoshida et al26 about 2 observations regarding fusion partners and
histologic features. Yoshida et al26 observed at least focal globular
immunoreactivity in 6 of 10 CD74-ROS1 rearrangement-positive
tumors; 2 of 3 of our CD74-ROS1epositive tumors had globules
and none of the others. Likewise, 3 of 4 EZR-ROS1 tumors
reported by Yoshida et al26 had membrane positivity, and our 1
tumor with an EZR-ROS1 rearrangement also showed strong
membrane positivity. Their only SLC-ROS1epositive tumor
did not have distinctive features, and neither did ours. Although
these combined numbers are still small, it does support the pos-
sibility that tumors with different fusion partners could stain
differently.
Conclusion
The results of our study have shown that ROS1 IHC is a sen-
sitive and speciﬁc method for detecting ROS1 gene rearrangements;Clinical Lung Cancer March 2015however, additional studies are needed to standardize specimen
processing, ROS1 staining, and ROS1 scoring. It could be impor-
tant to standardize tissue processing for lung cancer specimens, such
as has occurred for breast tissue processing for ERBB2 (HER2)
testing.26 A cost-effective algorithm for testing might be initial
testing of ROS1 using IHC, with a follow-up evaluation of tumors
with high ROS1 expression using RT-PCR or FISH for ROS1
rearrangements. IHC is a cost-effective and widely available method
that can identify the patients with lung cancers driven by ROS1
rearrangements who would be likely to beneﬁt from targeted
therapy.
Clinical Practice Points
 IHC is a cost-effective widely available method that could
be used to screen patients with lung cancer for ROS1
rearrangements.
 Multiple clinical studies have demonstrated the clinical efﬁcacy
of targeted therapy in patients with ROS1 rearrangement-driven
cancer.11
 FISH has been the reference standard for rearrangement detec-
tion but is expensive and cumbersome.
 The most practical algorithm to identify patients who might
beneﬁt from targeted therapy would be to screen all patients with
lung cancer for ROS1 overexpression using IHC and then perform
FISH analysis for those patients with equivocal to high ROS1
expression to speciﬁcally identify ROS1 genetic rearrangements.
Theresa A. Boyle et al We have proposed a standardized approach for ROS1 IHC
staining and scoring to screen for ROS1 rearrangements, a clin-
ically actionable genetic change in patients with lung cancer.Acknowledgments
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